Obinutuzumab in the treatment of patients with chronic lymphocytic leukemia and follicular lymphoma
03/2017
MUDr. Jana Zuchnická1, MUDr. Jana Fečková Mihályová1, MUDr. Juraj Ďuraš1,2, prof. MUDr. Roman Hájek, CSc.1,2
1 Klinika hematoonkologie FN Ostrava, 2 Lékařská fakulta OU, Ostrava
SUMMARY
Monoclonal antibodies are used in the treatment of chronic lymphocytic leukemia and follicular lymphoma especially in combination with chemotherapy. The introduction of rituximab into clinical practice meant a real turning point, it changed medical procedures and the results of the treatment of both diseases. As of recently new monoclonal antibodies are being introduced into clinical practice which are being developed to enhance the antitumor effect. One of them is a humanized monoclonal antibody obinutuzumab. Obinutuzumab combined with chlorambucil is in the Czech Republic approved for the treatment of chronic lymphocytic leukemia in previously untreated patients with multiple comorbidities, who can't undergo fludarabin based treatment. In follicular lymphoma the indication of using obinutuzumab in combination with bendamustine is used for treating patients with rituximab refractory follicular lymphoma, we refer to the current summary of product characteristics. The use of obinutuzumab for patients with follicular lymphoma in the Czech Republic is still bound to being approved by the payer according to §16 of Act No. 48/1997 Coll.
KEY WORDS
chronic lymfocytic leukemia, follicular lymphoma, monoclonal antibodies, obinutuzumab
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...